|
Nov 15
|
Sector Update: Health Care Stocks Slide Late Afternoon
|
|
Nov 15
|
Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline
|
|
Nov 15
|
Eyenovia Third Quarter 2024 Earnings: Misses Expectations
|
|
Nov 15
|
Eyenovia Provides Update on Phase 3 CHAPERONE Study
|
|
Nov 13
|
Eyenovia Inc (EYEN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
|
|
Nov 12
|
Eyenovia, Inc. (EYEN) Reports Q3 Loss, Misses Revenue Estimates
|
|
Nov 12
|
Eyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update
|
|
Oct 9
|
Eyenovia Inc (EYEN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
|
|
Oct 1
|
Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device
|
|
Sep 27
|
Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering
|
|
Sep 26
|
Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery
|
|
Jul 30
|
Eyenovia & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dry Eye Disease
|
|
May 15
|
Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol
|
|
May 14
|
Eyenovia to Report First Quarter 2024 Results on Wednesday, May 15th
|
|
May 10
|
Formosa and Tabuk sign deal for FDA-approved ophthalmic suspension
|
|
Apr 25
|
Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension
|
|
Apr 9
|
Eyenovia (EYEN) Down 18% on Disappointing Corporate Update
|
|
Apr 8
|
Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities
|
|
Apr 3
|
Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings
|
|
Mar 27
|
Q4 2023 NovaBay Pharmaceuticals Inc Earnings Call
|